BeOne Medicines (NASDAQ:ONC) Insider Lai Wang Sells 1,367 Shares

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) insider Lai Wang sold 1,367 shares of the firm’s stock in a transaction on Monday, June 8th. The shares were sold at an average price of $269.38, for a total value of $368,242.46. Following the sale, the insider directly owned 40 shares of the company’s stock, valued at $10,775.20. This represents a 97.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

BeOne Medicines Trading Down 1.7%

ONC stock opened at $263.61 on Thursday. The business has a fifty day moving average price of $301.03 and a 200 day moving average price of $315.60. BeOne Medicines Ltd. – Sponsored ADR has a fifty-two week low of $239.25 and a fifty-two week high of $385.22. The stock has a market capitalization of $28.92 billion, a price-to-earnings ratio of 58.97 and a beta of 0.49. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27.

BeOne Medicines (NASDAQ:ONC) last released its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%.The firm had revenue of $1.51 billion during the quarter. Analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ONC. EFG International AG bought a new position in shares of BeOne Medicines in the 4th quarter worth $25,000. Leonteq Securities AG bought a new position in shares of BeOne Medicines in the 4th quarter worth $35,000. Daiwa Securities Group Inc. bought a new position in shares of BeOne Medicines in the 2nd quarter worth $35,000. CWM LLC boosted its position in shares of BeOne Medicines by 32.8% in the 4th quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after purchasing an additional 39 shares during the last quarter. Finally, Group One Trading LLC bought a new position in shares of BeOne Medicines in the 4th quarter worth $61,000. 48.55% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have commented on ONC. Barclays increased their price objective on BeOne Medicines from $405.00 to $409.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Royal Bank Of Canada increased their price objective on BeOne Medicines from $425.00 to $436.00 and gave the company an “outperform” rating in a research report on Tuesday, June 2nd. Wells Fargo & Company began coverage on BeOne Medicines in a research report on Monday, May 4th. They issued an “overweight” rating and a $400.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of BeOne Medicines in a research report on Monday, April 20th. Finally, Guggenheim increased their price objective on BeOne Medicines from $410.00 to $420.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $390.00.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.